[논문]Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis - An 8-year prospective study

Stiehl, A.; Rudolph, G.; Sauer, P.; Benz, C.; Stremmel, W.; Walker, S.; Theilmann, L.

doi:10.1016/S0168-8278(97)80421-7

[해외논문] Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis - An 8-year prospective study

Journal of hepatology : the journal of the European Association for the Study of the Liver, v.26 no.3, 1997년, pp.560 - 566

Stiehl, A. (Department of Medicine, University of Heidelberg,, , FRG) , Rudolph, G. , Sauer, P. , Benz, C. , Stremmel, W. , Walker, S. , Theilmann, L.

Abstract ▼ AI-Helper

Background/Aims: Primary sclerosing cholangitis is characterized by progressive fibrotic inflammation and obliteration of intra- and extrahepatic bile ducts. Ursodeoxycholic acid treatment leads to improvement of biochemical parameters of cholestasis and in part also of liver histology. During treatment, obstruction of major ducts may lead to deterioration of liver function, which may be prevented by endoscopic dilation of the stenoses. Controlled trials for evaluation of the beneficial effects of ursodeoxycholic acid treatment and of endoscopic measures in patients with major duct stenoses have become clinically difficult. Estimation of survival probabilities without treatment allows comparison of actuarial survival with the estimated survival probabilities.Methods/Results: We studied survival in 65 patients with PSC treated with ursodeoxycholic acid (750 mg/day) and by endoscopic measures whenever necessary. Patients with decompensated cirrhosis in whom transplantation was foreseen were excluded. The study was started in May 1987 and the mean follow-up period was 45.0+/-3.5 (mean+/-SEM) months. Liver histology was performed in each of the patients before entry into the study and revealed that 21% were in stage 1, 37% in stage 2, 21% in stage 3 and 20% in stage 4. Of 65 patients, 12 had major duct stenosis at entry and another 11 developed major duct stenosis during ursodeoxycholic acid treatment, which was successfully treated by repeated endoscopic balloon dilations. The actuarial Kaplan-Meier survival probabilities without liver transplantation after treatment with ursodeoxycholic acid and dilation of major duct stenoses were significantly improved compared to the predicted survival rates with p=0.001.Conclusions: Ursodeoxycholic acid does not prevent major bile duct occlusion. When ursodeoxycholic acid treatment and endoscopic opening of duct stenoses are combined, survival may be significantly improved.

참고문헌 (39)

Gut Chapman 21 870 1980 10.1136/gut.21.10.870 Primary sclerosing cholangitis - a review of its clinical features, cholangiography and hepatic histology

상세보기
Gastroenterology Wiesner 79 200 1980 10.1016/0016-5085(80)90131-6 Clinicopathologic features of the syndrome of primary sclerosing cholangitis

상세보기
Gastroenterology Helzberg 92 1869 1987 10.1016/0016-5085(87)90618-4 Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients

상세보기
Am J Med Lindor 89 73 1990 10.1016/0002-9343(90)90101-I Advances in primary sclerosing cholangitis

상세보기
Gastroenterology Farrant 100 1710 1991 10.1016/0016-5085(91)90673-9 Natural history and prognostic variables in primary sclerosing cholangitis

상세보기
N Engl J Med Lee 332 924 1995 10.1056/NEJM199504063321406 Primary sclerosing cholangitis

상세보기
Br J Surg Ismail 78 564 1991 10.1002/bjs.1800780515 Primary sclerosing cholangitis: surgical options, prognostic variables and outcome

상세보기
Hepatology Wiesner 16 1290 1992 10.1002/hep.1840160527 Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis

상세보기
J Gastroenterol Hepatol Strasse 8 238 1993 10.1111/j.1440-1746.1993.tb01193.x Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: A comparison of complications and outcome

상세보기
Hepatology Narumi 22 451 1995 10.1002/hep.1840220213 Liver transplantation for sclerosing cholangitis

상세보기
Lancet Poupon i 834 1987 10.1016/S0140-6736(87)91610-2 Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

상세보기
Gastroenterology Leuschner 97 1268 1989 10.1016/0016-5085(89)91698-3 Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled doubleblind trial

상세보기
N Engl J Med Poupon 324 1548 1991 10.1056/NEJM199105303242204 A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis

상세보기
Hepatology Combes 22 759 1995 A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Gastroenterology Lindor 106 1284 1994 10.1016/0016-5085(94)90021-3 Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

상세보기
Hepatology Heathcote 19 1149 1994 10.1002/hep.1840190512 The Canadian multi-center double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis

상세보기
Gastroenterology Stiehl 94 595 1988 The effect of ursodeoxycholate in primary sclerosing cholangitis. A comparison to primary biliary cirrhosis
Gastroenterology Hayashi 99 533 1990 10.1016/0016-5085(90)91038-8 Symptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid

상세보기
J Hepatol Chazouilleres 11 120 1990 10.1016/0168-8278(90)90281-U Ursodeoxycholic acid for primary sclerosing cholangitis

상세보기
Hepatology O'Brien 14 838 1991 10.1002/hep.1840140516 Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30 months pilot study

상세보기
Gastroenterology Lebovics 102 2143 1992 10.1016/0016-5085(92)90345-Y Resolution of radiograhic abnormalities with ursodeoxycholic acid therapy of primary sclerosing cholangitis

상세보기
Hepatology Beuers 16 707 1992 10.1002/hep.1840160315 Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial

상세보기
J Hepatol Stiehl 20 57 1994 10.1016/S0168-8278(05)80467-2 Effects of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a place-controlled study period

상세보기
Gastroenterology Dickson 103 1893 1992 10.1016/0016-5085(92)91449-E Primary sclerosing cholangitis: Refinement and validation of survival models

상세보기
Surg Gynecol Obstet Abu-Elmagd 177 335 1993 Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis

상세보기
Hepatology Ludwig 1 632 1981 10.1002/hep.1840010612 Morphologic features and chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis

상세보기
Biometrics Woolson 37 687 1981 10.2307/2530150 Rank tests and a one-sample log rank test for comparing observed survival data to a standard population

상세보기
Biometrika Harrington 69 553 1982 10.1093/biomet/69.3.553 A class of rank test procedures for censored survival data

상세보기
Scand J Gastroent Stiehl 29 59 1994 10.3109/00365529409103626 Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis

상세보기
Dig Dis Sci Grijm 31 792 1986 10.1007/BF01296045 Therapeutic investigations in primary sclerosing cholangitis

상세보기
Gastrointest Endosc Johnson 33 9 1987 10.1016/S0016-5107(87)71475-8 Endoscopic treatment of biliary duct strictures in sclerosing cholangitis; Follow up assessment of a new therapeutic approach

상세보기
Huitbregtse 78-85 1988 Therapeutic investigations in primary sclerosing cholangitis
Semin Liver Dis Cotton 11 40 1991 10.1055/s-2008-1040421 Endoscopic and radiologic approaches to therapy in primary sclerosing cholangitis

상세보기
Eur J Gastroenterol Hepatol Craig 4 284 1992 Endoscopic therapy in primary sclerosing cholangitis
Am J Gastroenterol Gaing 88 2000 1993 Endoscopic management of primary sclerosing cholangitis review, and report of an open series

상세보기
Hepatology Lee 21 661 1995 Endoscopic therapy of sclerosing cholangitis
N Engl J Med Poupon 330 1342 1994 10.1056/NEJM199405123301903 Ursodiol for long-term therapy of primary biliary cirrhosis

상세보기
Am J Gastroenterol Simko 89 392 1994 Ursodeoxycholic therapy in chronic liver: A meta analysis in primary biliary cirrhosis and in chronic hepatitis
Gastroenterology Heathcote 108 A1082 1995 10.1016/0016-5085(95)28629-2 Combined analysis of French, American and Canadian randomized controlled trial of ursodeoxycholic acid therapy in primary biliary cirrhosis

상세보기

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

원문 URL 링크

DOI : 10.1016/S0168-8278(97)80421-7
European Association for the Study of the Liver : 저널
Elsevier : 저널

*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.

저작권 관리 안내

내보내기 메뉴

내보내기 구분

파일저장
인쇄
메일전송

구성항목

기본정보
상세정보

관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관

저장형식

Text(ASCII format)
Excel format
RefWorks Direct Export
RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley

메일정보

받는사람 (필수): @
보내는사람 (선택): @
제목
내용: KISTI 검색결과 이메일 서비스

안내

총 건의 자료가 검색되었습니다.

다운받으실 자료의 인덱스를 입력하세요. (1-10,000)

검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다.

데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요)

다운로드 파일은 UTF-8 형태로 저장됩니다.
파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오.

Text(ASCII format)
Excel format

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

AI-Helper ※ AI-Helper는 을 사용합니다.

AI-Helper

안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

연합인증